Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Simon J. Middendorp"'
Autor:
Jonas Wilbs, Xu-Dong Kong, Simon J. Middendorp, Raja Prince, Alida Cooke, Caitlin T. Demarest, Mai M. Abdelhafez, Kalliope Roberts, Nao Umei, Patrick Gonschorek, Christina Lamers, Kaycie Deyle, Robert Rieben, Keith E. Cook, Anne Angelillo-Scherrer, Christian Heinis
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-13 (2020)
Inhibiting thrombosis without inducing bleeding is a major challenge for anticoagulant agents. Here the authors describe a synthetic FXIIa inhibitor able to efficiently prevent thrombosis in mice and suppress coagulation in artificial lungs in rabbit
Externí odkaz:
https://doaj.org/article/1f9ddb75be1e4a398c1ff63698dcaa1b
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-9 (2017)
A major challenge for the application of peptide therapeutics is their short half-lifein vivo. Here, the authors design peptide-fatty acid chimeras bearing an engineered linker that promotes albumin binding and allows longer circulation times of ther
Externí odkaz:
https://doaj.org/article/cb4c3effd8b24083a11b07d420333e2b
Autor:
Claudia Quarroz, Simon J. Middendorp, Anne Angelillo-Scherrer, Jonas Wilbs, Sara Calzavarini, Christian Heinis
Publikováno v:
Middendorp, Simon Jan; Wilbs, Jonas; Quarroz, Claudia; Calzavarini, Sara; Angelillo-Scherrer, Anne; Heinis, Christian (2017). Peptide macrocycle inhibitor of coagulation factor XII with subnanomolar affinity and high target selectivity. Journal of medicinal chemistry, 60(3), pp. 1151-1158. American Chemical Society 10.1021/acs.jmedchem.6b01548
Factor XII (FXII) is a plasma protease that has emerged in recent years as a potential target to treat or prevent pathological thrombosis, to inhibit contact activation in extracorporeal circulation, and to treat the swelling disorder hereditary angi
Publikováno v:
Neuropharmacology. 95:459-467
GABAA receptors are the major inhibitory neurotransmitter receptors in the brain and are the target for many clinically important drugs such as the benzodiazepines. Benzodiazepines act at the high-affinity binding site at the α+/γ- subunit interfac
Autor:
Dirk Trauner, Simon J. Middendorp, Michael Pangerl, Erwin Sigel, Evelyn Hurni, Matthias Schönberger, Marco Stein
Publikováno v:
ACS chemical biology
GABAA receptors are the major inhibitory neurotransmitter receptors in the brain. Benzodiazepine exert their action via a high affinity-binding site at the α/γ subunit interface on some of these receptors. Diazepam has sedative, hypnotic, anxiolyti
Publikováno v:
ACS chemical biology
High throughput discovery of ligand scaffolds for target proteins can accelerate development of leads and drug candidates enormously. Here we describe an innovative workflow for the discovery of high affinity ligands for the benzodiazepine-binding si
Autor:
Ervin Pejo, Stuart A. Forman, Simon J. Middendorp, Valentina Carta, Marco Stein, Dirk Trauner, Erwin Sigel, Douglas E. Raines
Publikováno v:
Angewandte Chemie
Angewandte Chemie (International ed. in English)
Angewandte Chemie (International ed. in English)
Shine and rise! GABA(A) receptors are ligand-gated chloride ion channels that respond to γ-aminobutyric acid (GABA), which is the major inhibitory neurotransmitter of the mammalian central nervous system. Azobenzene derivatives of propofol, such as
Publikováno v:
The FASEB Journal. 28
Often novel high affinity ligands are required for a well-established target protein. Reasons include side effects, resistance development to or sub-optimal pharmacokinetic or pharmacodynamic prope...
Cyclic peptides binding to targets of interest can be generated efficiently with powerful in vitro display techniques, such as phage display or mRNA display. The cyclic peptide libraries screened with these methods are generated by altering in a comb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8cbbbb1d3871c56a42be5742e64e8ad
https://infoscience.epfl.ch/record/227015
https://infoscience.epfl.ch/record/227015
Publikováno v:
Nature Communications
Nature Communications, Vol 8, Iss 1, Pp 1-9 (2017)
Nature Communications, Vol 8, Iss 1, Pp 1-9 (2017)
The rapid renal clearance of peptides in vivo limits this attractive platform for the treatment of a broad range of diseases that require prolonged drug half-lives. An intriguing approach for extending peptide circulation times works through a ‘pig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fa032ffe035d8a1920c5d56712274d0
https://infoscience.epfl.ch/record/230656
https://infoscience.epfl.ch/record/230656